Pharmacogenetics of Efavirenz: Adherence and Virologic Outcomes

  1. David J. Cennimo, MD
  1. From University of Medicine and Dentistry of New Jersey, Newark, NJ 07103.

    TO THE EDITOR:

    Nachega and colleagues (1) describe the virologic response to nonnucleoside reverse transcriptase inhibitor (NNRTI) use across a spectrum of adherence in a predominantly (96.9%) black, South African patient cohort. Their findings suggest a …

    [Full Text of this Article]

    Summary for Patients

    • Article:Adherence to Nonnucleoside Reverse Transcriptase Inhibitor–Based HIV Therapy and Virologic Outcomes
      • Jean B. Nachega,
      • Michael Hislop,
      • David W. Dowdy,
      • Richard E. Chaisson,
      • Leon Regensberg,
      • and Gary Maartens
      Ann Intern Med April 17, 2007 146:564-573
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med December 4, 2007 vol. 147 no. 11 817
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)
      1. Summary for Patients

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. December 1, 2009, 151 (11)
    1. Alert me to current issues